Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849535 | 0.79 | HPGD (0.63) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL12468637 | 0.79 | HPGD (0.63) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL2249346 | 0.79 | HPGD (0.63) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL12588246 | 0.79 | LMNA (0.52) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL890219 | 0.79 | LMNA (0.65) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL26259 | 0.79 | LMNA (0.65) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL4949625 | 0.79 | LMNA (0.52) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL9221845 | 0.79 | LMNA (0.65) | LMNAMAPK1HPGDCES2CES1 | |
| Mandelic Acid SCHEMBL2689157 | 0.77 | LMNA (0.86) | LMNAMAPK1HPGDCES2CES1 | |
| SCHEMBL10536611 | 0.77 | LMNA (0.62) | LMNAMAPK1HPGDCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | claimed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| CN-110790673-A | Method for preparing O-tert-butyl-L-threonine tert-butyl ester | 熊飞龙 | 2020-02-14 | — | — | CN | disclosed |
| CN-110790674-A | Method for continuously producing O-tert-butyl-L-threonine tert-butyl ester | 熊飞龙 | 2020-02-14 | — | — | CN | disclosed |
| CN-103797020-A | P-chirality source organic phosphorus compound | CENTRE NAT RECH SCIENT | 2014-05-14 | — | — | CN | disclosed |
| CN-101155804-B | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMA CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-101395150-A | Phenethanolamine derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| CN-101155804-A | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMA CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5198448-A | Cardiovascular disorders | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| CN-1067053-A | Pyrazines derivatives and preparation method thereof | OTSUKA PHARMA CO LTD (JP) | 1992-12-16 | — | — | CN | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| CN-1017708-B | METHOD FOR PREPARATION OF PYRAZOLOTRIAZINE COMPOUNDS | OTSUKA CHEMICAL CO LTD (JP) | 1992-08-05 | — | — | CN | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| CN-1051178-A | New heterogeneous ring compound and preparation method thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1991-05-08 | — | — | CN | disclosed |
| EP-0355583-A2 | Cardiotonics | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| CN-87107217-A | Method for preparation of pyrazolotriazine compounds | — | 1988-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | LMNA 1437/4885MAPK1 1175/4885HPGD 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.